Here is how ChromaDex (CDXC) and Bioventus (BVS) have performed compared to their sector so far this year.
Here is how ChromaDex (CDXC) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.
ChromaDex (CDXC) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.03 per share a year ago.
ChromaDex Corporation is a leader in NAD+ development for healthy aging with Tru Niagen, showing strong growth and attractive valuation. ChromaDex is making a move into the pharma industry with NRC candidate for AT, receiving FDA designations and preparing for clinical trials. Potential risks include cash burn, competition, and IP challenges, but the company's dual focus on pharma and nutraceuticals offers significant upside.
ChromaDex (CDXC) rises 12% as the FDA grants the Orphan Drug Designation and the Rare Pediatric Disease Designation to its investigational candidate, NRC, to treat ataxia telangiectasia.